QED Technologies (United States)

Recent papers from QED Technologies (United States)

1. Millimetre-wave comb generated by an optical microcombNature Communications · 2026
2. Multi-Messenger Framework for Exoplanet Biosignature Detection: Methodology, Bayesian Evidence Framework, False-Positive Rejection, and Transit Timing Variation Analysis2026
3. Hyperadhesive von Willebrand Factor Contributes to Pathogenesis of PreeclampsiaArteriosclerosis Thrombosis and Vascular Biology · 2026
4. Double-Hybrid, but Not Double-Cost: GPU-Accelerated DHDFT for the COMPAS-3 Data Set of Polybenzenoid HydrocarbonsJournal of Chemical Theory and Computation · 2026
5. Interpretable multivariate survival models: Improving predictions for conversion from mild cognitive impairment to Alzheimer's disease via data fusion and machine learning.2026
6. Efficient Algorithms for GPU Accelerated Evaluation of the DFT Exchange-Correlation FunctionalJournal of Chemical Theory and Computation · 2025
7. High-Performance, High-Angular-Momentum J Engine on Graphics Processing UnitsJournal of Chemical Theory and Computation · 2025
8. Efficient Algorithms for GPU Accelerated Evaluation of the DFT Exchange-Correlation Functional2025
9. Thermal state structure in the Tavis-Cummings model and rapid simulations in mesoscopic quantum ensemblesPhysical Review Research · 2025
10. Acceleration of Self-Consistent Field Calculations Using Basis Set Projection and Many-Body Expansion as Initial Guess MethodsJournal of Chemical Theory and Computation · 2025
11. Low–dose infigratinib increases bone growth and corrects growth plate abnormalities in an achondroplasia mouse modelJournal of Bone and Mineral Research · 2024
12. Infigratinib, a selective FGFR1‐3 tyrosine kinase inhibitor, alters dentoalveolar development at high dosesDevelopmental Dynamics · 2023
13. Nano–Calcium Carbonate Affect the Respiratory and Function Through Inducing Oxidative StressJournal of Occupational and Environmental Medicine · 2022
14. Targeting FGFR3 Alterations with Adjuvant Infigratinib in Invasive Urothelial Carcinoma: the Phase III PROOF 302 TrialFuture Oncology · 2022
15. Post-concussive mTBI in Student Athletes: MRI Features and Machine LearningFrontiers in Neurology · 2022
16. Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studiesTherapeutic Advances in Musculoskeletal Disease · 2022
17. Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial CarcinomaClinical Genitourinary Cancer · 2021
18. Silicon crystals for steering high-intensity particle beams at ultrahigh-energy acceleratorsPhysical Review Research · 2021
19. Time-resolved imaging of correlation-driven charge migration in light-induced molecular magnets by X-ray scatteringFaraday Discussions · 2020
20. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistanceBritish Journal of Cancer · 2020